Spots Global Cancer Trial Database for Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

Official Title: Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement

Study ID: NCT06131489

Conditions

Hemophagocytic Lymphohistiocytosis

Epstein-Barr Virus

Bowel Resection

Interventions

Segmental bowel resection combined with the DEP regimen

Study Description

Brief Summary: EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Detailed Description: Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.